Cart
sales@molnova.com
Vebicorvir
CAS No. 2090064-66-5
Vebicorvir( ABI-H0731 )
Catalog No. M23939 CAS No. 2090064-66-5
Vebicorvir is a first-generation hepatitis B virus (HBV) core protein inhibitor, has demonstrated effective antiviral activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 149 | In Stock |
|
| 10MG | 239 | In Stock |
|
| 25MG | 487 | In Stock |
|
| 50MG | 593 | In Stock |
|
| 100MG | 844 | In Stock |
|
| 200MG | 1143 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameVebicorvir
-
NoteResearch use only, not for human use.
-
Brief DescriptionVebicorvir is a first-generation hepatitis B virus (HBV) core protein inhibitor, has demonstrated effective antiviral activity.
-
DescriptionVebicorvir is a first-generation hepatitis B virus (HBV) core protein inhibitor, has demonstrated effective antiviral activity.
-
In VitroVebicorvir (ABI-H0731) demonstrates inhibition of pgRNA, HBeAg, and HBsAg production, with EC50s of 2.68?μM, 4.95?μM, and 7.30?μM, respectively.Vebicorvir (ABI-H0731) is an inhibitor of pgRNA encapsidation and rcDNA synthesis.
-
In VivoAfter i.v. administration, the drug rapidly distributes and decayes in a biphasic manner in all species tested. Plasma clearance values of ABI-H0731 were 8.05, 10.1, 14.7, and 4.86?ml/min/kg, representing 9, 16, 47, and 11% of liver blood flow, in mouse, rat, dog, and monkey, respectively.
-
SynonymsABI-H0731
-
PathwayMicrobiology/Virology
-
TargetHBV
-
RecptorHBV DNA
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2090064-66-5
-
Formula Weight467.44
-
Molecular FormulaC19H12F3N3O4S2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (213.93 mM)
-
SMILESO=C(c(cc1)cc(NC(c2c3cccc2)=O)c1S3(=O)=O)NCc1cnc(C(F)(F)F)s1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Huang Q, Cai D, Yan R, Li L, Zong Y, Guo L, Mercier A, Zhou Y, Tang A, Henne K, Colonno R. Preclinical Profile and Characterization of the Hepatitis B Virus Core Protein Inhibitor ABI-H0731. Antimicrob Agents Chemother. 2020 Oct 20;64(11):e01463-20.
molnova catalog
related products
-
GLP-26
GLP-26 is a novel potent HBV capsid modulator that reduces secreted HBeAg in HepNTCPDL cells transfected with HBV wild type with EC50 of 0.7 uM.
-
Hepatitis B Virus Co...
The hepatitis B virus (HBV) core protein has been found in the nucleus, the cytoplasm, or both of HBV-infected hepatocytes. nuclear localization of the HBV core protein is negatively regulated by phosphorylation during the cell cycle.
-
ccc_R08
ccc_R08 is an orally available HBV cccDNA inhibitor that reduces extracellular levels of HBV DNA, HBsAg, and HBeAg in a dose-dependent manner. ccc_R08 is investigational for use in the treatment of HBV infections. ccc_R08 has been shown to be effective in the treatment of hepatitis C virus (HCV).
